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Background: Cardiac involvement determines outcome in patients with systemic amyloidosis. There is
major unmet need for quantiﬁcation of cardiac amyloid burden, which is currently only met in part
through semi-quantitative bone scintigraphy or Cardiovascular Magnetic Resonance (CMR), which
measures ECVCMR. Other accessible tests are needed.
Objectives: To develop cardiac computed tomography to diagnose and quantify cardiac amyloidosis by
measuring the myocardial Extracellular Volume, ECVCT.
Methods: Twenty-six patients (21 male, 64 ± 14 years) with a biopsy-proven systemic amyloidosis (ATTR
n ¼ 18; AL n ¼ 8) were compared with twenty-seven patients (19 male, 68 ± 8 years) with severe aortic
stenosis (AS). All patients had undergone echocardiography, bone scintigraphy, NT-pro-BNP measure-
ment and EQ-CMR. Dynamic Equilibrium CT (DynEQ-CT) was performed using a prospectively gated
cardiac scan prior to and after (5 and 15 minutes) a standard Iodixanol (1 ml/kg) bolus to measure ECVCT.
ECVCT was compared to the reference ECVCMR and conventional amyloid measures: bone scintigraphy
and clinical markers of cardiac amyloid severity (NT-pro-BNP, Troponin, LVEF, LV mass, LA and RA area).
Results: ECVCT and ECVCMR results were well correlated (r
2 ¼ 0.85 vs r2 ¼ 0.74 for 5 and 15 minutes post
bolus respectively). ECVCT was higher in amyloidosis than AS (0.54 ± 0.11 vs 0.28 ± 0.04, p<0.001) with no
overlap. ECVCT tracked clinical markers of cardiac amyloid severity (NT-pro-BNP, Troponin, LVEF, LV mass,
LA and RA area), and bone scintigraphy amyloid burden (p<0.001).
Conclusion: Dynamic Equilibrium CT, a 5 minute contrast-enhanced gated cardiac CT, has potential for
non-invasive diagnosis and quantiﬁcation of cardiac amyloidosis.
© 2015 The Authors. Published by Elsevier Inc. on behalf of Society of Cardiovascular Computed
Tomography. This is an open access article under the CC BY license (http://creativecommons.org/licenses/
by/4.0/).rast Cardiovascular Magnetic
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Systemic amyloidosis is a multisystem disease caused by the
deposition of misfolded ﬁbrillar protein in tissues and organs
causing expansion of the extracellular space and impairment of
function.1,2 Cardiac involvement is a leading cause of morbidity and
mortality, with two types commonly inﬁltrating the ventricular
myocardium: immunoglobulin light-chain (AL) type and trans-
thyretin (ATTR) type.3e5 With current or pending new treatment
options for both,6,7 improved diagnosis of cardiac involvement is
becoming increasingly important. However current clinicalscular Computed Tomography. This is an open access article under the CC BY license
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Invasive cardiac biopsy is prone to sampling error and unsuitable
for monitoring therapy. Although certain types of bone scintig-
raphy10,11 and conventional cardiovascular magnetic resonance
(CMR) late gadolinium enhancement (LGE)12 can detect cardiac
amyloid, neither is truly quantitative and both have limitations e
for example, bone tracers are insensitive in AL amyloidosis and SAP
scintigraphy does not image cardiac amyloid.
Extracellular volume fraction (ECV) quantiﬁed by Equilibrium
Contrast CMR (EQ-CMR) tracks amyloid burden.13 Equilibrium
Computed Tomography can also quantify the ECV frompre and post
contrast measurements of attenuation, and shows good correlation
with ECV measured by EQ-CMR as well as histological measures of
myocardial ﬁbrosis.14e16 CT has advantages over CMR: ubiquitously
available equipment, higher spatial resolution and a simple linear
relationship between attenuation (Hounsﬁeld units) and iodine
concentration as opposed to the nonlinear effect on relaxivity of
hydrogen following administration of gadolinium.
This study was designed to simplify the progenitor equilibrium
methods by using a bolus-only, dynamic equilibrium approach
(DynEQ-CT) and apply it to an important clinical problem: the non-
invasive diagnosis and quantiﬁcation of cardiac amyloid burden.
Our objectives were three-fold: ﬁrstly, to evaluate optimal post
bolus contrast timing for DynEQ-CT; secondly, to assess the ability
to quantify myocardial amyloid against conventional semi-
quantitative methods (bone scintingraphy) and clinical markers
of cardiac dysfunction; and thirdly, to compare ECVCT against
ECVCMR.
Material and methods
All research was carried out at University College London Hos-
pital and the Royal Free NHS Trusts, London, UK, between January
2013 and December 2013. The study was approved by the ethical
committee of U.K. National Research Ethics Service (REC reference
09/H0716/75) and conformed to the principles of the Helsinki
Declaration. All subjects gave written informed consent to partici-
pate in the study. Exclusion criteria were uncontrolled arrhythmia,
impaired renal function (estimated glomerular ﬁltration rate
<60 mL/min), or contraindications to MR imaging (e.g. implanted
devices e exclusion from CMR only). A total of 53 patients were
recruited: 26 with systemic amyloidosis (ATTR and AL) and 27
comparator controls with aortic stenosis. All patients underwent
12-lead ECG, DynEQ-CT, EQ-CMR, echocardiography for diastolic
function assessment according to European Society of Echocardi-
ography criteria,17 assays of NT-proBNP and 6-minute walk test
where health and patient choice permitted (e.g. arthritis, postural
hypotension, neuropathy). Troponin T was measured in amyloid
patients only. The ATTR group also underwent bone scintigraphy
using 3,3-diphosphono-1,2-propanodicarboxylicacid (DPD).10
Amyloid patients
26 patients with systemic amyloidosis were recruited. Eighteen
patients had ATTR amyloidosis (16 male, age 68 ± 8 years), and
eight patients (5 male, age 56 ± 12 years) had systemic AL
amyloidosis. For ATTR, cardiac amyloidosis was deﬁned by presence
of ATTR amyloid in a myocardial biopsy (Congo red and immuno-
histochemical staining) or positive DPD scintigraphy; 6 TTR pa-
tients had positive myocardial biopsies.10 Deﬁnite cardiac
involvement by DPD was deﬁned as DPD grade 2 or 3, and possible
cardiac involvement as grade 1 (i.e. minimal cardiac DPD uptake) in
the absence of LVH; in practice, none of these patients had LVH. All
TTR patients also underwent sequencing of exons 2, 3, and 4 of the
TTR gene: 14 had senile systemic amyloid (SSA) and four TTRpatients were familial (V122I [n ¼ 1], V30M [n ¼ 1], E54G [n ¼ 2]).
For AL, systemic AL amyloidosis was proven with biopsies from
non-cardiac tissues. Cardiac categorization was based on interna-
tional consensus criteria18 but with an additional “possible
involvement” category, as previously described.19 Overall, 21 pa-
tients were categorized as having deﬁnite cardiac amyloidosis (14
ATTR; 7 AL) and 5 patients (4 ATTR; 1 AL) as having possible cardiac
involvement.
Comparator group
Twenty-seven age- and sex-matched patients with severe aortic
stenosis (19 male, age 68 ± 8 years) underwent DynEQ-CT and CMR
(n ¼ 22 with 5 exclusions due to claustrophobia or pacemaker). AS
was chosen as a comparator for having LV remodeling and hyper-
trophy, and allowing for cardiac amyloid to be excluded histologi-
cally on myocardial biopsy (Congo red staining) taken during aortic
valve surgery as part of a separate study.
DynEQ-CT Protocol
The DynEQ-CT protocol consisted of three steps (Fig. 1 for ﬂow
chart): ﬁrst, a CT scan to obtain baseline pre-contrast blood and
myocardial attenuation in Hounsﬁeld units (HU); second, contrast
administration and delay so the contrast distributes into a blood:-
myocardial dynamic equilibration; third, a repeat scan to re-
measure blood and myocardial attenuation. The ratio of the
change in blood and myocardial attenuation (DHU) represents the
contrast agent partition coefﬁcient. If the blood volume of distri-
bution is substituted in (1 minus venous hematocrit; obtained prior
to imaging), the myocardial extracellular volume, ECVCT, is ob-
tained, reﬂecting the myocardial interstitium:
ECVCT ¼ (1Hematocrit)  (DHUtissue/DHUblood).
CT examinations were performed on a 64edetector row CT
scanner (Somatom Sensation 64; Siemens Medical Solutions,
Erlangen, Germany). A topogramwas used to plan CT volumes from
the level of the aortic valve to the inferior aspect of the heart,
typically a 10 cm slab. Cardiac scans (tube voltage, 120 kV; tube
currentetime product, 160 mAs; section collimation, 64 detector
rows, 1.2-mm section thickness; gantry rotation time, 330 msec)
were acquired with prospective gating (65%e75% of R-R interval),
and reconstructed into 3-mm-thick axial sections with a B20f
kernel.
To establish the best timing, post contrast imaging was per-
formed at both 5- and 15-minutes following a bolus of Iodixanol
(652 mg/mL) at a standard dose of 1 mL/kg and injection rate of
3 ml/sec without a saline chaser. An additional single 3 mm slice
acquisition at 1-minute (other parameters as previously described)
was introduced in the amyloid cohort to aid blood:myocardial
boundary detection for segmentation of the myocardium during
analysis.
CT image analysis was performed using a free and open-source
Digital Imaging and Communications in Medicine viewer (OsiriX
v4.1.2; Pixmeo, Bernex, Switzerland) independently by two expe-
rienced readers blinded to all other study data; this was repeated
by the second reader to establish inter- and intra-observer agree-
ment. Regions of interest (ROIs) were drawn in the contrast-
enhanced 1-minute acquisition in axial sections and propagated
to the pre-contrast, 5-minute and 15-minute acquisitions. For
myocardium, polygonal ROIs were drawn in an axial slice con-
taining the greatest area of myocardial septum; for the blood pool,
circular ROIs were drawn in the LV blood pool away from papillary
muscles and the myocardial septum to avoid the endocardial edge
and therefore partial voluming (Fig. 2). Myocardial and blood
attenuation values were used to calculate the ECV fraction as
Fig. 1. PseudoEQ Cardiac CT and EQ-CMR Protocols: EQ-CMR was performed either after or at least 24 hours prior to the CT to avoid residual gadolinium causing an increase in
measured attenuation. The CMR protocol for amyloidosis is 3.5  longer than the CT protocol.
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Signal-to-noise ratios (SNR) were measured in ﬁve myocardial
ROIs per time point from the ratio of the average HU attenuation
value to the standard deviation of the HU attenuation. Radiation
exposure was quantiﬁed using the dose-length product multiplied
by a chest conversion coefﬁcient (k ¼ 0.014 mSv/mGy cm).20
EQ-CMR protocol
EQ-CMR was performed using a 1.5-T scanner (Avanto; Siemens
Medical Imaging, Erlangen, Germany) either after or at least
24 hours prior to the CT to avoid residual gadolinium causing an
increase in measured attenuation. In addition to the standard CMR
protocol (Fig. 1 for ﬂow chart), T1 mapping for ECVCMR quantiﬁca-
tion was performed using ShMOLLI (Shortened Modiﬁed Look-
Locker Inversion recovery),21 providing a single-section T1 map in
one breath-hold.22 For CMR image analysis, a large ROI was drawn
manually by a reader blinded to the clinical data on each image to
define the septum and blood pool; source data and errormapswere
used for quality control (Fig. 2).23
99mTc-DPD bone scintigraphy
For the ATTR patients, bone scintigraphy as a semiquantitative
test of myocardial amyloid burden was performed as previously
described.10,11 Cardiac retention of 99mTc-DPD was visually scored
as: Grade 0 e no myocardial uptake; Grade 1 emild cardiac uptake
with no signiﬁcant attenuation of normal bony uptake; Grade 2 e
moderate cardiac uptake with some attenuation of the bone signal;
Grade 3 e strong cardiac uptake with little or no bone uptake.
Statistical analysis
A statistical package (SPSS, version 22) was used for all data
analysis. Continuous variables were expressed as mean ± SD and
non-parametric variables as median with inter-quartile. Theassociation between ECVCT and ECVCMR was assessed by using
Pearson correlation; normal distribution was assessed by using the
ShapiroWilkinson test. Agreement between ECVCT and ECVCMR was
assessed by Bland-Altman comparison. A p value <0.05 was
considered statistically signiﬁcant.Results
Baseline characteristics of twenty-six systemic amyloidosis and
twenty-seven AS patients are shown in Table 1. Compared to AS,
patients with amyloidosis had a signiﬁcantly higher LV mass
(116 ± 40 vs 103 ± 27 g/m2; p¼ 0.05), higher indexed left atrial area
(15.3 ± 3.4 vs 13.2 ± 3.7 cm2/m2; p¼ 0.05), lower LVEF (59 ± 15 vs
69 ± 13%; p¼ 0.02), lower indexed stroke volume (42 ± 10 vs
50 ± 13 ml/m2; p¼ 0.04), worse diastolic function (E/A ratio:
1.46 ± 0.94 vs 0.93 ± 0.55 ml/m2; p¼ 0.02) and shorter distance on
6-minute walk test (356 ± 136 vs 469 ± 168 m; p¼ 0.01). There was
no signiﬁcant between group difference in systolic or diastolic
blood pressure, NT-proBNP or Troponin.Technical development: DynEQ-CT ECV performance at 5 and
15 minutes
Comparison of the signal to noise ratios showed that the SNR
was signiﬁcantly higher in the 5 minute rather than 15 minute scan
(4.7 ± 0.9 vs 3.9 ± 0.9, p<0.001). ECVCT at 5 minutes was strongly
correlated with ECVCMR (r2 ¼ 0.85, p<0.001) but correlation was
weaker at 15 minutes (r2 ¼ 0.74, p<0.001; Fig. 3). Bland-Altman
comparisons of ECVCT and ECVCMR demonstrated no bias at 5 mi-
nutes post contrast, with slight bias at 15 minutes (4%, no slope).
Compared to the 5 minute time point, the 95% conﬁdence limits
were nearly twice as wide at 15 minutes (95% conﬁdence
limits: 18%, 22% vs 11%, 11%).
The mean total calculated effective radiation dose for the whole
DynEQ-CT protocol (including both post contrast time points) was
1.56 mSv ± 0.58 mSv, with a mean administered total Iodixanol
Fig. 2. Examples of typical CMR and CT analysis: Top row displays regions of interest (ROIs) in CMR T1 maps images acquired before (A) and after gadolinium contrast (B). Middle
and bottom rows show ROIs in gated cardiac CT images acquired pre-contrast (C), 1 minute (D), 5 and 15 minutes post iodine contrast (E þ F). ROIs were drawn in the myocardial
septum and blood pool.
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For DynEQ-CT, inter- and intra-observer agreement was excel-
lent for myocardial (ICC ¼ 0.92 and ICC ¼ 0.94, respectively) and
blood pool (ICC ¼ 0.96 and ICC ¼ 0.99, respectively) attenuation
measurements. Similarly for ECV, excellent agreement was found
(ICC ¼ 0.95 and ICC ¼ 0.98, respectively).
Diagnosis of cardiac amyloid by ECV
ECVCT was signiﬁcantly higher in amyloid patients with deﬁni-
tive cardiac involvement than aortic stenosis (0.54 ± 0.11 versus
0.28± 0.04, p<0.001; Fig. 4). Like ECVCMR, ECVCT discriminated 100%
between amyloid patients with deﬁnitive cardiac involvement and
patients with aortic stenosis (ie there was no overlap in ECV be-
tween the two cohorts). Furthermore, ECVCT showed a higher ECV
in ATTR than AL amyloidosis (0.56 ± 0.11 versus 0.43 ± 0.12,
p¼ 0.03), but with wide overlap between groups.
ECV tracks clinical parameters
ECVCT tracked clinical parameters as equally well as CMR, with
DynEQ-CT ECV at 5 minutes consistently better than at 15 minutes(Table 2): for the 5 minute results, ECVCT increased with increasing
index LV mass (r ¼ 0.43, p¼ 0.003), increasing indexed LAA
(r ¼ 0.49, p¼ 0.001), lower LV ejection fraction (r ¼ 0.45,
p¼ 0.002), worse LV diastolic function (E/A ratio: r¼ 0.51, p<0.001),
reduced distance on 6MWT (r ¼ 0.35, p¼ 0.02), increasing NT-pro-
BNP levels (r ¼ 0.66, p¼ 0.001) and Troponin T levels (r ¼ 0.49,
p¼ 0.03). In ATTR amyloid, ECVCT tracked amyloid burden semi-
quantitatively measured by DPD bone scintigraphy (p<0.001)
(Fig. 5).Discussion
This study showed that measuring the myocardial extracellular
volume, ECVCT, using a simple 5-minute, gated cardiac CT protocol,
DynEQ-CT, can distinguish cardiac amyloidosis from another dis-
ease with myocardial hypertrophy, aortic stenosis. ECVCT is a
quantitative parameter and compares well with the previously
validated standard of ECVCMR but is easier and quicker to measure.
ECVCT tracked cardiac amyloid burden, which is a major marker of
outcome in systemic amyloidosis. This protocol can simply be
added to routine CT coronary angiography protocols with only a
small increase in radiation dose. It has the potential to offer a
Table 1
Baseline characteristics of amyloidosis and aortic stenosis patients.
Systemic Amyloidosis Comparator with Aortic Stenosis p-value
N 26 27
Men/women 21/5 19/8
Age, yrs 64 ± 14 68 ± 8 0.2
eGFR, ml/min/1.73 m2 71 ± 11 78 ± 19 0.1
LV structure by CMR
Indexed LV mass, g/m2 116 ± 40 103 ± 27 0.05
Indexed LA area, cm2/m2 15.3 ± 3.4 13.2 ± 3.7 0.05
LV systolic function by CMR
LVEF, % 59 ± 15 69 ± 13 0.02
Indexed SV, ml/m2 42 ± 10 50 ± 13 0.02
Echocardiography
E-wave 0.86 ± 0.20 0.73 ± 0.32 0.08
E/A 1.46 ± 0.94 0.93 ± 0.55 0.02
E/E0 14.7 ± 7.2 13 ± 8 0.1
E-deceleration time, ms 178 ± 54 246 ± 76 0.001
Aortic Valve Peak Gradient 7 ± 1 68 ± 21 0.001
Clinical Parameters
6 minutes walking test, meters 356 ± 130 469 ± 168 0.01
SBP (mmHg) 129 ± 22 131 ± 18 0.5
DBP (mmHg) 76 ± 12 74 ± 11 0.3
Atrial Fibrillation 3 (11.5%) 2 (8%)
Biomarkers
NT-proBNP, pmol/L 356 (24-1426) 155 (8-568) 0.04
Troponin T, pmol/L 0.080 (0.01-0.24) NA
Values are mean ± SD or %.
Patients with systemic amyloidosis encompassing light-chain and transthyretin amyloidosis and aortic stenosis patients with severe stenosis awaiting valve replacement.
eGFR, estimated glomerular ﬁltration rate; NT-proBNP, N-terminal pro-brain natriuretic peptide; CMR, cardiovascular magnetic resonance; EDV, end diastolic volume; ESV,
end systolic volume; LVEF, left ventricular ejection fraction; SV, stroke volume; LV, left ventricular; LAA, left atrial area.
Fig. 3. Correlation and agreement of ECV derived by CT and CMR: Top row show ECVCMR and ECVCT correlations; the 5 minute CT (A) correlates better than at 15 minutes (B)
(r2 ¼ 0.85 vs r2 ¼ 0.74; p<0.001). Bottom row shows Bland-Altman comparisons of the ECV measurement by CMR versus CT at 5 minutes (C) and 15 minutes (D). ECV differences are
expressed as a percentage, calculated by subtracting ECVCT from ECVCMR) against mean ECV (solid thick line), with lower (bottom thin line) and upper (top thin line) 95% limits of
agreement.
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Fig. 4. ECV in patients with deﬁnite cardiac amyloidosis: Myocardial ECV by DynEQ-CT
at 5 minutes was higher in all patients with deﬁnitive cardiac amyloidosis than in
patients with severe aortic stenosis (0.54 ± 0.11 vs 0.28 ± 0.04, p < 0.001).
Table 2
Correlations between ECVCT and ECVCMR with clinical parameters.
ECVCMR (R) ECVCT 5-minutes (R) ECVCT 15-minutes (R)
LV structure by CMR
Indexed LV mass, g/m2 0.40z 0.43z 0.44z
Indexed LA area,cm2/m2 0.45z 0.49z 0.45y
LV systolic function by CMR
LVEF, % 0.46y 0.43y 0.38y
Indexed SV,ml/m2 0.34y 0.28 ns 0.25 ns
LV diastolic function by echo
E 0.47z 0.35y 0.24 ns
E/A 0.52z 0.51z 0.43z
E/E0 0.48z 0.49z 0.47z
E-deceleration time, ms 0.50z 0.45z 0.40z
Clinical Parameters
SBP (mmHg) 0.43y 0.26 ns 0.35y
DBP (mmHg) 0.15 ns 0.08 ns 0.06 ns
6 minutes walking test, meters 0.39z 0.35y 0.24 ns
Biomarkers
NT-proBNP, pmol/L 0.59z 0.64z 0.45y
Troponin T, pmol/L 0.50y 0.49y 0.0.6 ns
zP < 0.01 level; yP < 0.05; ns non-signiﬁcant.
R ¼ Pearson correlation coefﬁcient; CMR, cardiovascular magnetic resonance; CT, computed tomography; ECV, extracellular volume fraction; NT-proBNP, N-terminal pro-
brain natriuretic peptide; EDV, end diastolic volume; ESV, end systolic volume; LVEF, left ventricular ejection fraction; SV, stroke volume; LV, left ventricular; LAA, left
atrial area.
Fig. 5. ECV tracks amyloid burden measured by DPD bone scintigraphy: ECV vs DPD
grade in 26 patients with systemic amyloidosis (27 patients with aortic stenosis used
as comparator e no evidence of cardiac involvement on myocardial biopsy).
T.A. Treibel et al. / Journal of Cardiovascular Computed Tomography 9 (2015) 585e592590unique insight into the myocardial interstitium and provide a new
diagnostic test for an under-diagnosed and now treatable cause of
LVH and heart failure: cardiac amyloidosis.
Our previous protocol using a primed infusion to reach contrast
equilibrium was logistically cumbersome and time consuming,
therefore development of a bolus-only approach brings ECV, this
promising novel biomarker, a step closer to routine clinical appli-
cability. In our paper we show disease-speciﬁc utility of the CT
approach. Furthermore, we unequivocally demonstrated that im-
aging at 5 minutes post bolus was superior to acquisition at
15 minutes, with superior SNR, correlation to the ECVCMR, corre-
lation to clinical parameters known to track cardiac disease, and to
semiquantitative bone tracer scanning results in TTR amyloid. The
theoretical advantage of allowing equilibration of the iodineconcentration in myocardium and blood between the 5 minute and
15 minute scan is out-weighed by the loss in signal due to overall
lower iodine concentrations. Peculiar to cardiac amyloid, as the ECV
is so high, early post contrast images may not allow easy identiﬁ-
cation of the boundary betweenmyocardium and blood. This is due
to the myocardial ECV being as high or even higher than that of the
plasma such that pre and post contrast attenuation are very similar.
The addition of a low dose, early arterial phase scan facilitated
blood myocardial segmentation overall. The resulting triple phase
scan using a 64 slice scanner had a mean overall radiation dose of
1.5 mSv e signiﬁcantly lower than conventionally used bone tracer
scintigraphy (4 mSv).
Comparison to previous CTECV work is limited to two studies by
Nacif and colleagues comparing heart failure patients with
T.A. Treibel et al. / Journal of Cardiovascular Computed Tomography 9 (2015) 585e592 591controls: In the ﬁrst study, subjects underwent CMR and CCT with
CTECV and yielding results in line with the CMR ECV literature and
similar to our AS cohort (28.6 ± 4.4% vs 31.6 ± 5.1%, p¼ 0.03).15 In
the second study, whole heart 3D ECV was quantiﬁed; ECV was
substantially higher than in the previous CT study by the same
group and in CMRECV studies (41 ± 6%, 33 ± 2%; p¼ 0.02),16 raising
the concern that the partial voluming of the blood pool may have
occurred. In this context, our CT ECV results in conﬁrmed cardiac
amyloidosis were 6 standard deviations higher than in the control
subjects.
From a diagnostic perspective, ECVCT was higher in patients
with deﬁnite cardiac amyloidosis than the comparator group with
LVH due to AS with no overlap, which mirrored previous ﬁndings
by ECVCMR. Furthermore, ECVCT correlated with established
markers of cardiac amyloid severity using structural and functional
(LVEF and SV) parameters, biomarkers, and function capacity as
well as cardiac amyloid burden measured semi-quantitatively by
bone tracer scintigraphy. Although the role of cellular hypertrophy
and diffuse ﬁbrosis is unknown in cardiac amyloid, the ECV
expansion seen with amyloid deposition is ten times larger than
that seen with diffuse ﬁbrosis in aortic stenosis, hypertension or
hypertrophic cardiomyopathy.24e26
The ECVCT technique carries some advantages in clinical prac-
tice; CMR is not suitable in around 10% of patients (due to claus-
trophobia or many cardiac pacemakers). Furthermore, there are
concerns that the CMR signal is affected by limits to the fast ex-
change of protons (this does not apply to CT).23 The CT approach is
cheaper, completed in 5 minutes, and widely available, providing
high-resolution 3D ECV volumes with two single breath-hold ac-
quisitions, and the scanner design can accommodate patients with
obesity and claustrophobia. Although it has a lower signal to noise
ratio, and probably more dependency on a reasonable eGFR, ECVCT
therefore has several advantages over ECVCMR.Limitations and future steps
In this study, the DynEQ-CT techniquewas compared to the best,
currently available non-invasive techniques for the quantiﬁcation
of ECV (EQ-CMR) and TTR amyloid burden (DPD scintigraphy), but
no invasive biopsy data was available for this validation. However,
with the patchy distribution of cardiac amyloid deposits, biopsy
data may not be superior. DynEQ-CT and EQ-CMR only identify
general cardiac amyloid deposition (which is important to trigger
therapy); tissue diagnosis is still necessary, but can be achieved
from more accessible, non-cardiac tissue in this systemic disease.
The data presented here is from a small study in a single specialized
center, aimed to be hypothesis generating. A larger study is
required to test these, develop this test further, and compare the
head-to-head diagnostic performance of CT and CMR. The 64-slice-
CT-system employed heremay reﬂect themost commonly available
systems available, but does not take advantage of newer systems
that offer iterative reconstruction algorithms, dual energy acquisi-
tion and larger detector arrays that allow acquisition of whole
heart, isotropic volumes of in one heart beat and at low radiation
dose. In conjunction with 3D image registration and processing,
this allows creation of whole heart ECV maps.16 Given the exposure
to ionizing radiation, patients with severe aortic stenosis were
deemed as adequate control cohort, avoiding exposure of healthy
volunteers. Furthermore, AS patients were age-/gender-matched
and had ventricular hypertrophy. As a research project, we limited
the study to subjects with an eGFR of >60, a signiﬁcant limitation
for AL amyloid where 50% of patients with signiﬁcant amyloid have
renal impairment.Conclusion
DynEQ-CT is a simple 5-minute, gated, easily implementable
contrast-enhanced cardiac CT scan that can quantify cardiac amy-
loid burden, track disease severity and appears to be as effective as
cardiovascular MR. Advantages over cardiovascular MR include
scanner availability and cost, reduced examination time and
applicability to those with CMR contraindications.
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